Losses falling by 75 percent while revenue surges 50 percent
As India's earnings season unfolds ahead of May 29 trading, the market finds itself confronting the ancient tension between promise and performance — some companies narrowing losses and surging forward, others stumbling despite modest growth. From edtech to automobiles, pharmaceuticals to food delivery, the quarter's results reveal an economy in uneven motion, where regulatory milestones, governance thresholds, and infrastructure contracts quietly shape the longer arc of corporate destiny. The day's announcements remind us that markets are not merely ledgers of profit and loss, but living records of human ambition navigating uncertainty.
- Bata India's profit cratered 95.2% to just Rs 2.2 crore — a stark reminder that even legacy brands are not immune to the weight of restructuring costs and shifting consumer habits.
- Swiggy's shareholder vote on IOCC status fell agonizingly short at 72.36%, missing the 75% special resolution threshold by less than three percentage points, leaving its foreign exchange regulatory ambitions in limbo.
- Physicswallah and GMR Airports offered counternarratives of genuine momentum — one slashing losses by nearly 75%, the other swinging from a Rs 237.6 crore loss to a Rs 302.4 crore profit on the back of strong revenue expansion.
- India's pharma sector advanced on multiple regulatory fronts simultaneously — FDA clearance for Lupin, a new antibiotic approval for Wockhardt, EU GMP certification for Indoco, and Priority Review status for Zydus — signaling a sector in active global ascent.
- The government's decision to exercise the oversubscription option in Coal India's offer-for-sale effectively doubled the divestment to 2%, reflecting confidence in market appetite even as Patanjali Foods absorbed a Rs 1,352.9 crore tax demand.
On the eve of May 29 trading, Indian markets prepared for a session dense with quarterly results and corporate announcements spanning edtech, automobiles, pharmaceuticals, and food delivery — a day that would test investor appetite across a wide and uneven landscape.
The earnings picture was one of sharp contrasts. Physicswallah narrowed its losses dramatically, from Rs 293.1 crore to Rs 74.9 crore, while growing revenue 50.7% to Rs 918.8 crore — a company visibly moving toward profitability without yet arriving. Ashok Leyland delivered cleaner momentum, with profit rising 14.2% to Rs 1,290.7 crore on revenue growth of 17.4%. The story darkened elsewhere: Bata India's profit collapsed 95.2% to Rs 2.2 crore, weighed down partly by Rs 28 crore in voluntary retirement scheme costs, while Deepak Fertilisers saw earnings fall nearly half despite modest revenue gains. GMR Airports offered the quarter's most dramatic reversal, swinging from a Rs 237.6 crore loss to a Rs 302.4 crore profit on 37.5% revenue growth.
Swiggy encountered a governance obstacle when its shareholder vote on amendments meant to establish IOCC status under foreign exchange regulations secured only 72.36% approval — short of the 75% threshold required. The company faces further conditions, including achieving resident Indian shareholding above 50%, before the designation can be realized.
India's pharmaceutical sector moved on several regulatory fronts at once. Lupin received FDA inspection clearance for its Ankleshwar facility. Wockhardt won approval to market Zaynich, a novel antibiotic combination targeting complicated urinary tract infections. Indoco Remedies earned EU GMP certification from German authorities for its Baddi plant. Zydus Lifesciences gained FDA Priority Review for saroglitazar, a treatment for primary biliary cholangitis, with a decision expected by late November.
Infrastructure companies announced contracts that would anchor future revenues — HG Infra winning a Rs 114.5 crore annual transmission system contract in Jharkhand over 35 years, and Suyog Urja securing a Rs 207.5 crore hybrid renewable energy project. In capital markets, mutual funds reshuffled positions in Pine Labs and Indoco Remedies, while the government doubled its Coal India divestment to 2% by exercising an oversubscription option. Patanjali Foods, meanwhile, absorbed a Rs 1,352.9 crore tax demand from Chennai authorities over alleged turnover and TDS discrepancies for 2022-23 — a reminder that regulatory risk runs alongside opportunity in equal measure.
On the eve of May 29 trading, Indian markets were bracing for a day crowded with quarterly results and corporate announcements that would test investor appetite across sectors as disparate as edtech, automobiles, pharmaceuticals, and food delivery.
The earnings season painted a portrait of uneven recovery. Physicswallah, the online education platform, reported a significant narrowing of its losses—down to Rs 74.9 crore from Rs 293.1 crore a year earlier—while simultaneously posting revenue growth of 50.7 percent to Rs 918.8 crore. The trajectory suggested a company moving toward profitability, though not yet there. Ashok Leyland told a different story of momentum: profit climbed 14.2 percent to Rs 1,290.7 crore on the back of revenue that surged 17.4 percent to Rs 17,246.4 crore. But the results were not uniformly bright. Bata India's profit collapsed 95.2 percent to just Rs 2.2 crore despite modest 5 percent revenue growth, a decline partly attributable to Rs 28 crore in voluntary retirement scheme expenses. Deepak Fertilisers saw profit sink nearly half, falling 49.7 percent to Rs 139.4 crore, even as revenue inched up 12.9 percent. The pattern repeated across other names: PC Jeweller surged with 61.3 percent profit growth, while PG Electroplast's earnings plunged 55.3 percent. GMR Airports swung from a loss of Rs 237.6 crore to a profit of Rs 302.4 crore, a turnaround powered by 37.5 percent revenue expansion to Rs 3,938.2 crore.
Beyond the numbers, several companies announced developments that would shape their trajectories. Swiggy, the food delivery giant, faced a governance hurdle when shareholders voted on amendments to its Articles of Association intended to position the company as an Indian Owned and Controlled Company under foreign exchange regulations. The vote secured 72.36 percent approval—falling short of the 75 percent threshold required for a special resolution by 2.64 percentage points. The company would need to clear additional hurdles, including achieving resident Indian shareholding exceeding 50 percent, before achieving IOCC status.
In pharmaceuticals, multiple firms advanced their regulatory standing. Lupin received an Establishment Inspection Report from the U.S. Food and Drug Administration following a pre-approval inspection of its Ankleshwar facility in Gujarat conducted in early March. Wockhardt secured Central Drugs Standard Control Organisation approval to import and market Zaynich, an antibiotic combining zidebactam and cefepime, for treating complicated urinary tract infections in adults. Indoco Remedies obtained EU GMP certification from German health authorities for its oral solid dosage manufacturing plant in Baddi, Himachal Pradesh, following an inspection in late April. Zydus Lifesciences' subsidiary received Priority Review designation from the FDA for a new drug application covering saroglitazar, a treatment for primary biliary cholangitis, with a decision expected by late November.
Infrastructure and industrial companies announced contract wins that would support future revenue. HG Infra Engineering was named successful bidder to establish an inter-state transmission system in Jharkhand worth Rs 114.5 crore annually over 35 years. Enviro Infra Engineers' subsidiary, Suyog Urja, secured a Rs 207.5 crore contract for a hybrid renewable energy project. Escorts Kubota introduced Kubota Neostar, an upgraded compact tractor line targeting the 21-30 horsepower segment, with initial focus on sugarcane, vineyard, and horticulture regions across Maharashtra, Karnataka, Madhya Pradesh, and Gujarat.
In capital markets activity, mutual funds reshuffled their holdings. SBI Mutual Fund acquired an additional 1.3 crore shares in fintech platform Pine Labs for Rs 177.79 crore at Rs 135 per share, while Nippon India Mutual Fund bought 70 lakh shares at the same price. Simultaneously, venture capital fund Altimeter Growth Partners Fund III LP exited its position, selling 1.56 crore Pine Labs shares for Rs 211.08 crore. ICICI Prudential Mutual Fund picked up a 1.47 percent stake in Indoco Remedies for Rs 26.88 crore. Promoter Authum Investment & Infrastructure continued building its stake in Prataap Snacks, acquiring an additional 1.3 lakh shares at Rs 1,123.15 per share.
The government, meanwhile, expanded its divestment plans. The decision to exercise an oversubscription option in Coal India's offer-for-sale meant the total stake being sold would double to 2 percent, or 12.32 crore shares, up from the base offer of 6.16 crore shares. Reliance Industries scheduled its 49th Annual General Meeting for June 19. And Patanjali Foods faced a tax notice from the Chennai office of the Assistant Commissioner demanding Rs 1,352.9 crore plus penalties and interest related to alleged discrepancies in reported turnover and TDS deductions for the 2022-23 period. The day ahead promised to be one where market participants would sift through winners and losers, regulatory progress and setbacks, all while watching whether Swiggy could find a path forward on its governance challenge.
Citações Notáveis
The proposed amendments were a preparatory step towards the company's objective of qualifying as an Indian Owned and Controlled Company under applicable Indian foreign exchange laws and regulations.— Swiggy corporate filing
HG Infra Engineering declared as successful bidder by REC Power Development & Consultancy to establish inter-state transmission system worth Rs 114.5 crore per year in Jharkhand for 35 years.— HG Infra Engineering announcement
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that Physicswallah is still losing money if the losses are shrinking so dramatically?
Because it tells you the company is on a trajectory. Fifty percent revenue growth with losses falling by 75 percent suggests they're approaching the inflection point where the business turns profitable. Investors watch for that signal.
And Bata India—that's a collapse, isn't it? Ninety-five percent profit drop?
It is, but the revenue only fell 5 percent. The real story is the Rs 28 crore in voluntary retirement costs. Strip that out and the underlying business didn't crater. Still, it signals the company is restructuring, which raises questions about whether they're adapting fast enough.
What's the significance of Swiggy missing that 75 percent threshold by less than 3 percent?
It's frustrating for them because they were so close. The IOCC classification matters for foreign exchange compliance and long-term operational flexibility in India. But missing it by 2.64 percent means they'll likely try again—they have the support, just not quite enough. It's a delay, not a defeat.
Why are so many pharma companies getting regulatory approvals at the same time?
It's not coincidence. These inspections and approvals take months to process. You see clusters because companies file applications in waves, and the regulatory bodies work through them in batches. When you see multiple pharma approvals in one day, it often means the pipeline is healthy.
The infrastructure contracts—are those significant?
Very. A 35-year transmission contract worth Rs 114.5 crore annually is predictable, long-term revenue. For companies like HG Infra, that's the kind of contract that stabilizes cash flow and attracts investors. It's not flashy, but it's foundational.
What does the mutual fund activity tell you about market sentiment?
It's mixed. SBI and Nippon buying Pine Labs at the same price suggests confidence in that valuation. But Altimeter exiting at a higher price means they're taking profits. Both can be true—some investors see upside, others think they've captured their gains.